PCG-1, a novel brown fat PPARgamma coactivator
AssigneeDana-Farber Cancer Institute, Inc.
InventorsBruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
Life of this patent
Estimating the term…
Loading patent…
AssigneeDana-Farber Cancer Institute, Inc.
InventorsBruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
Estimating the term…
The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
An isolated nucleic acid molecule comprising a nucleotide sequence encoding PGC-1 or a portion thereof.
An isolated nucleic acid molecule comprising a nucleotide sequence encoding a protein or a portion thereof, wherein the protein or portion thereof comprises an amino acid sequence which is sufficiently homologous to an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5 such that the protein or portion thereof maintains the ability to modulate one or more of the following biological activities:
An isolated nucleic acid molecule at least 15 nucleotides in length which hybridizes to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:4.
An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:4 or a nucleotide sequence which is at least about 60% homologous to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:4.
An isolated nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5 or an amino acid sequence which is at least about 60% homologous to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5.
An isolated nucleic acid molecule encoding a PGC-1 fusion protein.
A vector comprising a nucleotide sequence encoding PGC-1.
An isolated PGC-1 protein or a portion thereof which can modulate one or more of the following biological activities:
An isolated protein or a portion thereof which comprises an amino acid sequence which is sufficiently homologous to an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5 such that the protein or portion thereof maintains the ability to modulate one or more of the following biological activities:
An isolated protein comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5 or an amino acid sequence which is at least about 60% homologous to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5.
A fusion protein comprising a PGC-1 polypeptide operatively linked to a non-PGC-1 polypeptide.
An antigenic peptide of PGC-1 comprising at least 8 amino acid residues of the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:5, the peptide comprising an epitope of PGC-1 such that an antibody raised against the peptide forms a specific immune complex with PGC-1.
An antibody that specifically binds PGC-1.
A method for detecting the presence of PGC-1 in a biological sample comprising contacting a biological sample with an agent capable of detecting PGC-1 protein or mRNA.
A kit for detecting the presence of PGC-1 in a biological sample comprising a labeled or labelable agent capable of detecting PGC-1 protein or mRNA in a biological sample;
A method for identifying a compound capable of treating a disorder characterized by aberrant PGC-1 nucleic acid expression or PGC-1 protein activity comprising assaying the ability of the compound or agent to modulate the expression of PGC-1 nucleic acid or the activity of the PGC-1 protein thereby identifying a compound capable of treating a disorder characterized by aberrant PGC-1 nucleic acid expression or PGC-1 protein activity.
A method for identifying a compound which binds to PGC-1 protein comprising contacting the PGC-1 protein with the compound under conditions which allow binding of the compound to the PGC-1 protein to form a complex;
A method for identifying a compound which inhibits the interaction of the PGC-1 protein with a target molecule comprising contacting, in the presence of the compound, the PGC-1 protein and the target molecule under conditions which allow binding of the target molecule to the PGC-1 protein to form a complex;
Dependencies are inferred from the claim text.